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Abstract 
Thyroid hormones are essential for normal development and function of human 
skeleton. Both excess as well as deficiency of thyroid hormones lead to disturbance 
of bone metabolism. Consequently, the disorder of bone formation   and bone 
resorption phases can cause loss of bone mass and fractures. The aim of this study is 
to investigate better markers of bone metabolism pathologies during thyroid 
disfunction. 
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Introduction  
For normal functioning of bone metabolism, harmonious roles of different factors 
are vital, such as genetic condition, hormonal and metabolic homeostatis, balanced 
diet, and mechanical load (Raisz, 2005). The disturbance of these systems can lead 
to serious and dangerous consequences, the prevention of which requires a correct 
adjustment (Raisz, 2005). Any abnormalities and irregularities of bone 
mineralization lead to significant changes for the human body such as bone length 
reduction and deformations and fractures (Raisz, 2005). The rising number of 
diagnosed osteoporosis cases in society makes it important to study all secondary 
conditions which can lead to reduced bone mineral density (Raisz, 2005). 
The thyroid hormone plays a pivotal role in normal skeletal development and is 
essential for bone remodeling processing (Harvey et al., 2002). More than 120 years 
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ago, Von Recklinghausen described a correlation between multiple fractures and the 
state of hyperthyroidism, and these studies and discussions are still ongoing as 
thyroid dysfunctions are widespread on a global scale (Nicholls et al., 2012). 
The thyroid hormone receptors TRα1, TRβ1 and TRβ2 regulate expression of target 
genes in response to T3 (Forrest et al., 1990). TRα1 and TRβ1 are present in growth 
plate chondrocytes, bone marrow stromal cells, bone-forming osteoblasts, 
coordinating bone formation and bone resorption in the skeleton. Additionally, TRα1 
and TRβ1 mediate the action of the biologically active hormone 3,5,3′-L-
triiodothyronine (T3) in the bone, which demonstrates a close relationship between 
thyroid dysfunction and bone metabolism (Forrest et al., 1990; Robson et al., 2000; 
Gauthier et al., 2000). 
Both cases of thyroid disfunction, hyperthyroidism and hypothyroidism, disturb 
bone metabolism and change the balance of bone formation and bone resorption 
markers (Williams and Bassett, 2018; Bakos et al., 2018). 
The excess of thyroid hormones in childhood can lead to premature growth of plates, 
closure of cranial sutures, causing low growth and deformation of the skeleton. In 
adults, hyperthyroidism is characterized by accelerated bone renewal and a loss of 
mineral density in 10-20% of a study group. The bone remodeling cycle is reduced 
in almost 50%, dropping from 200 to 113 days, and the proportions between bone 
formation and its resorption are inhibited (Basset & Williams, 2003; Harvey et al., 
2002; Basset & Williams, 2008; Greenspan & Greenspan, 1999; Stevens et al., 2003; 
Williams, 2009). The bone formation phase decreases by 2/3, which effects a loss of 
more than 10% of the mineralized bone in one cycle. As a result, thyrotoxicosis leads 
to increased risk of fractures (Lakatos, 2003; Kosińska et al., 2005).    
On the contrary, deficiency of thyroid hormones in childhood leads to growth 
retardation or even growth arrest, disturbances of endochondral ossification, delayed 
bone age and persistent short stature (Basset & Williams, 2003; Harvey et al., 2002; 
Basset & Williams, 2008; Greenspan and Greenspan, 1999; Stevens et al., 2003; 
Williams, 2009). Hypothyroidism causes general hypometabolism. Bone formation 
processes are slowed in 50% in hypothyroid patients and bone resorption processes 
in 40%, although their mechanism remains unclear (Lakatos, 2003; Kosińska et al., 
2005).    
Biochemical markers released during bone remodeling by osteoblasts and 
osteoclasts can be evaluated in the blood (Greenblatt et al., 2017; Ale et al., 2018). 
In our study, we investigate osteocalcin as a bone turnover marker and beta-
CrossLaps as a bone resorption marker. 
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Osteocalcin (OSC) is the most important non-collagen bone matrix protein and 
accounts for about 1% of the total bone protein. Osteocalcin is synthesized in 
osteoblasts and is widely known as a marker of osteoblastic bone activity (Greenblatt 
et al., 2017; Cancela et al., 1990; Ale et al., 2018). After releasing from the 
osteoblasts, osteocalcin is not only assimilated into the bone matrix, but also secreted 
into the blood stream and is therefore termed a bone turnover marker and is used for 
this purpose (Gouveia et al., 2001; Varga et al., 1997; Tsevis et al., 2018). 
More than 90 % of organic bone matrix consists of type I collagen, which is 
preferentially synthesized in bone. There is regulated anabolism and catabolism of 
the basic substance in bone (Greenblatt et al., 2017; Markus, 2005). During normal 
bone metabolism, mature type I collagen is degraded, and small fragments pass into 
the bloodstream and are excreted via the kidneys. In physiologically or 
pathologically elevated bone resorption (e.g. in old age or as a result of osteoporosis), 
type I collagen is degraded to an increased extent, and there is a commensurate rise 
in the level of collagen fragments in the blood (Greenblatt et al., 2017; Markus, 
2005). By determining these bone resorption markers, the activity of osteoclasts can 
be detected. Especially relevant collagen type I fragments are the β-isomerized 
C-terminal telopeptides (β-CrossLaps or β-CTx). These isomerized telopeptides are 
highly specific for the degradation of type I collagen dominant in bone (Greenblatt 
et al., 2017). Elevated serum levels of isomerized C-terminal telopeptides of type I 
collagen have been reported for patients with increased bone resorption and return 
to normal levels during antiresorptive therapy (Markus, 2005).  
 
Materials and methods  
Clinical samples for the study were collected during a one-year period from January 
to November 2019 at the Central Laboratory of the Surgical Clinic Azerbaijan 
Medical University, Baku, Azerbaijan. Suitable patients attending the Outpatient 
Department for evaluation of thyroid status were enrolled in the study. 
Twenty hyperthyroid (16 female, 4 male) and twenty hypothyroid (17 female, 3 
male) patients aged 20-60 years were selected for the study. The control group also 
included 20 healthy patients with no history of chronic disease from ages 25-35 
years. The patients were diagnosed as Graves disease, multinodular goiter and 
Hashimoto disease. Patients with co-morbidity, such as vitamin D deficiency, renal 
disease, alcoholism and patients on medication influencing bone turnover were 
excluded from the study. 
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The diagnosis was based on their detailed medical history and thyroid profile 
analysis (TSH, free T3 and free T4). Fasting venous blood samples were collected 
from patients and control subjects under the sterile condition. The samples were 
centrifuged to obtain serum on the same day of collection for further clinical 
analysis. All samples were stored at -20ºС.   
Quantitative determination of serum osteocalcin (N-MID Osteocalcin) and beta-
CrossLaps (β-CrossLaps/serum) bone markers were analyzed by 
electrochemiluminescent (ECLIA) enzyme immunoassay for in-vitro diagnostic 
using a Roche cobas e 411 analyzer (Delmas et al., 2000; Christgau et al., 1998; 
Markus, 2006). For the thyroid profile (TSH, freeT3, freeT4) analysis the Roche 
cobas e 411 analyzer (ECLIA method) was also used. 
The results of all variables are reported as the mean±S.D. Independent t-test and 
Pearson correlation were used to compare the difference of the values between 
hyper- and hypo-thyroid state and control patients. The analysis was performed by 
using GraphPad Prism software. The p-value <0.05 was considered as statistically 
significant and p<0.0001 as statistically highly significant. 
 
Results 
The identification criteria for diagnosis of hyperthyroid patients were applied for 
elevated levels of active thyroid hormones and lowered level of TSH. Free 
Trijodthyronin (fT3) (6.57±2.22 vs. 3.49±0.53, p-value <0.0001), free Thyroxine 
(fT4) (22.45±5.53 vs. 13.62±1.61, p-value <0.0001) in the serum were higher and 
the TSH level in hyperthyroid state was significantly lower than that of controls 
(0.134±0.22 vs. 1.45±0.68 p-value <0.0001).    
Table 1. Serum bone turnover markers and thyroid hormones of patients in 
hyperthyroid state and controls. 
Parameters 
 
Hyperthyroid state 
(n=20) 
Mean±SD 
Control 
(n=20) 
Mean±SD 
p-value 
Osteocalcin (ng/mL) 25.42±11.57 15.44±3.49 0.0025 
β-CrossLaps (ng/mL) 0.477±0.309 0.244±0.07 0.0063 
TSH (µIU/mL) 0.134±0.22 1.45±0.68 0.0001 
Free Trijodthyronin (pmol/L) 6.57±2.22 3.49±0.53 0.0001 
Free Thyroxine (pmol/L) 22.45±5.53 13.62±1.61 0.0001 
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Results are expressed as a Mean±Standart Deviation (SD). Statistical analysis was 
performed by unpaired t-test. p<0.05 Statistically Significant, p<0.0001 Statistically 
highly significant, p>0.05 Statistically not significant. 
Hypothyroidism is associated with low levels of thyroid hormones, high level of 
TSH, and the signs and symptoms as well. Free Trijodthyronin (fT3) (1.58±0.65 vs. 
3.49±0.53, p-value <0.0001) and free Thyroxine (fT4) (8.15±1.54 vs. 13.62±1.61, p-
value <0.0001) were highly decreased in hypothyroid patients, while serum TSH 
(19.3±17.54 vs. 1.45±0.68, p-value <0.0001) was increased in relation to the control 
group.  
Table 2. Serum bone turnover markers and thyroid hormones of patients in 
hypothyroid state and controls. 
Parameters 
 
Hypothyroid state 
(n=20) 
Mean±SD 
Control 
(n=20) 
Mean±SD 
p-value 
Osteocalcin (ng/mL) 20.43±6.05 15.44±3.49 0.0010 
β-CrossLaps (ng/mL) 0.430±0.194 0.244±0.07 0.0001 
TSH (µIU/mL) 19.3±17.54 1.45±0.68 0.0001 
FreeTrijodthyronin(pmol/L) 1.58±0.65 3.49±0.53 0.0001 
Free Thyroxine (pmol/L) 8.15±1.54 13.62±1.61 0.0001 
 
Results are expressed as a Mean±Standart Deviation (SD). Statistical analysis was 
performed by unpaired t-test. p<0.05 Statistically Significant, p<0.0001 Statistically 
highly significant, p>0.05 Statistically not significant. 
                   
Serum bone marker levels, osteocalcin and β-CrossLaps, were higher in 
hyperthyroidism in relation to the control group (25.42±11.57 vs. 15.44±3.49 ng/mL, 
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p=0.0025 and 0.477±0.309 vs. 0.244±0.07 ng/mL, p=0.0063, respectively). In our 
study, the osteocalcin level in hypothyroid patients does not have a large deviation 
in comparison with the control group (20.43±6.05 vs.15.44±3.49 p=0.0010). 
However, the bone resorption marker β-CrossLaps in hypothyroidism was 
significantly increased in comparison to the control patients (0.430±0.194 vs. 
0.244±0.07 p=0.0001). 
In both hyperthyroid and hypothyroid states, we found a strong correlation between 
OSC and β-CrossLaps levels, with r=0.805 p<0.01 and r=0.672 p<0.01 respectively, 
which were statistically significant (p less than 0.001).  These results of our 
investigation suggest that osteoblastic activity is enhanced in hyperthyroidism and 
suppressed in hypothyroidism. Consequently, the analysis of both biochemical bone 
metabolism markers has/plays an important role in thyroid patients. In the 
hypothyroid state, bone resorption processes proceed more intensively, than during 
bone remodeling processes, so the β-CrossLaps marker is a better marker for the 
detection of osteoporosis in hypothyroidism (Varga et al., 2010; Murphy & 
Williams, 2004; Vestergaard and Bassett, 2002).   
 
Discussion 
Recent studies reveal that thyroid status has a significant role in bone metabolism 
regulation (Murphy and Williams, 2004). The excess of thyroid hormones leads to 
increased bone resorption and formation activity (De Leo et al., 2016; Bassett & 
Williams, 2016; Reddy et al., 2012; Svare et al., 2009). A meta-analysis by 
Vestergard et al. (2003) noted that bone mass density was significantly decreased in 
patients with untreated hyperthyroidism. 
The expedited bone remodeling and reduced bone density in hyperthyroidism 
increases the risk of fracture and osteoporosis, which can be detected by elevated 
levels of bone markers (Vestergaard & Bassett, 2002; Fitzpatrick, 2002; Gorka et 
al., 2013; Reddy et al., 2012; Svare et al., 2009).  
In our investigation, the hyperthyroid patients had highly significant elevated 
osteocalcin and β-CrossLaps. Kisakol et al. (2003), also showed a high level of 
osteocalcin in their study as a marker increasing during osteoblastic activity. A 
similar study by Barsal et al. (2004), reported that bone formation and bone 
resorption marker levels are elevated in hyperthyroid patients, which confirms the 
high bone turnover state.   
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Thyroid hormones bind to nuclear receptors and regulate gene transcription via 
interaction with thyroid hormone response elements of specific genes (Waung et al., 
2011; Gauthier et al., 1999).  The action of active thyroid hormone formed in bone 
are complex and partially understood (Waung et al., 2011). Thyroid hormones 
stimulate both bone formation and resorption. During bone formation, fT3 stimulates 
osteoblast proliferation, differentiation and apoptosis, and increases the expression 
of osteocalcin, type 1 collagen, alkaline phosphatase, metalloproteins, IGF-1 and its. 
It also amplifies the effects of interleukin-1, interleukin-6, and prostaglandin E2 
during bone resorption receptor (Basset and Williams, 2003; Harvey et al., 2002; 
Williams, 2009; Bassett & Williams, 2016).   
TSH acts as a direct negative regulator of bone turnover, that hinders osteoblast 
differentiation and repress osteoclast formation (Abe et al., 2003).   
Contrasting with hyperfunction of thyroid hormones, hypothyroidism leads to a low 
bone turnover, with a reduction of osteoclast bone resorption and of osteoblast 
formation (Bassett et al., 2007; Fitzpatrick, 2002; Gallford et al., 2005; Waung et 
al., 2011). The hypothyroid state slows the remodeling process and increases the 
time taken in the remodeling cycle. This is due to the prolongation of the 
mineralization phase (Bassett et al., 2007; Fitzpatrick, 2002; Vestergaard, 2002; 
Gallford et al., 2005). Vestergaard (2002) histomorphometry data demonstrated that 
hypothyroidism is associated with a two- to three- fold increased risk of fracture, 
which is related mainly with hypometabolism, "metabolic depression" and tissue 
hypoxia. Impaired growth and differentiation cells and tissues, physiological 
regeneration slows down, but bone resorption passes faster and because of this/as a 
result/as its consequence, the bone resorption marker β-CrossLaps (p-value<0.0001) 
becomes significantly elevated.  
Therefore, based on our study and recent studies, early management of thyroid 
disorders is essential for the prevention bone related complication. 
 
Conclusion 
Thyroid hormones are essential for normal development and function of the human 
skeleton. In hyper- and hypo-thyroidism, the conditions observed increased fracture 
risk (Fitzpatrick, 2002; Vestergaard and Mosekilde, 2003; Leger et al., 1997). Our 
recent study suggests that osteocalcin and β-CrossLaps markers are non-invasive 
markers, which can be used in the investigation and prevention pathologies of bone 
metabolism during thyroid disfunction. 
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